U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H29N9O3.2ClH
Molecular Weight 588.489
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LISAVANBULIN DIHYDROCHLORIDE

SMILES

Cl.Cl.NCCCC[C@H](N)C(=O)NC1=CC=C(C=C1)C(=O)CN2C(=NC3=C2C=CC=C3)C4=NON=C4NCCC#N

InChI

InChIKey=AOKATNWVGVIXOQ-TXEPZDRESA-N
InChI=1S/C26H29N9O3.2ClH/c27-13-4-3-6-19(29)26(37)31-18-11-9-17(10-12-18)22(36)16-35-21-8-2-1-7-20(21)32-25(35)23-24(34-38-33-23)30-15-5-14-28;;/h1-2,7-12,19H,3-6,13,15-16,27,29H2,(H,30,34)(H,31,37);2*1H/t19-;;/m0../s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C26H29N9O3
Molecular Weight 515.567
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Lisavanbulin, also known as BAL-101553, a prodrug of the molecule BAL-27862 with potential antitumor activity. BAL-27862 binds to tubulin, prevents tubulin polymerization, destabilizes microtubules, arrests tumor cell proliferation, and induces cell death in cancer cells. Lisavanbulin participated in phase II clinical trials for the treatment of advanced solid tumors. Besides, the drug participates in a 1/2a clinical study in patients with recurrent glioblastoma and in patients with platinum-resistant or refractory ovarian cancer. In this study, will be characterized the safety and tolerability and to obtain efficacy data in these selected cancer types.

Approval Year

PubMed

PubMed

TitleDatePubMed
The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.
2017-09
The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells.
2016-11
Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.
2015-06
The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
2014-04-17

Sample Use Guides

BAL101553 48-hour infusion on day 1, 8, and 15 of each 28-day cycle; oral capsule daily for one week during Cycle 2 Oral daily administration of BAL101553
Route of Administration: Other
Substance Class Chemical
Created
by admin
on Tue Apr 01 16:26:53 GMT 2025
Edited
by admin
on Tue Apr 01 16:26:53 GMT 2025
Record UNII
5BQ16RIM5D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BAL-101553 DIHYDROCHLORIDE
Preferred Name English
LISAVANBULIN DIHYDROCHLORIDE
Common Name English
HEXANAMIDE, 2,6-DIAMINO-N-(4-(2-(2-(4-((2-CYANOETHYL)AMINO)-1,2,5-OXADIAZOL-3-YL)-1H-BENZIMIDAZOL-1-YL)ACETYL)PHENYL)-, HYDROCHLORIDE (1:2), (2S)-
Systematic Name English
Code System Code Type Description
PUBCHEM
45259013
Created by admin on Tue Apr 01 16:26:53 GMT 2025 , Edited by admin on Tue Apr 01 16:26:53 GMT 2025
PRIMARY
CAS
1387574-54-0
Created by admin on Tue Apr 01 16:26:53 GMT 2025 , Edited by admin on Tue Apr 01 16:26:53 GMT 2025
PRIMARY
SMS_ID
300000013059
Created by admin on Tue Apr 01 16:26:53 GMT 2025 , Edited by admin on Tue Apr 01 16:26:53 GMT 2025
PRIMARY
FDA UNII
5BQ16RIM5D
Created by admin on Tue Apr 01 16:26:53 GMT 2025 , Edited by admin on Tue Apr 01 16:26:53 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY